Phase I trial of bortezomib daily dose: Safety, pharmacokinetic profile, biological effects, and early clinical evaluation in patients with advanced solid tumors.

2014 ◽  
Vol 32 (15_suppl) ◽  
pp. 2623-2623
Author(s):  
Rastislav Bahleda ◽  
Marie-Cécile Le Deley ◽  
Apexa Bernard ◽  
Shalini Chaturvedi ◽  
Anas Gazzah ◽  
...  
Keyword(s):  
Phase I ◽  
Solid Tumors ◽  
Clinical Evaluation ◽  
Phase I Trial ◽  
Biological Effects ◽  
Pharmacokinetic Profile ◽  
Advanced Solid Tumors ◽  
Daily Dose

Phase I trial of bortezomib daily dose: safety, pharmacokinetic profile, biological effects and early clinical evaluation in patients with advanced solid tumors

2017 ◽  
Vol 36 (4) ◽  
pp. 619-628 ◽  
Author(s):  
Rastislav Bahleda ◽  
Marie-Cécile Le Deley ◽  
Apexa Bernard ◽  
Shalini Chaturvedi ◽  
Michael Hanley ◽  
...  
Keyword(s):  
Phase I ◽  
Solid Tumors ◽  
Clinical Evaluation ◽  
Phase I Trial ◽  
Biological Effects ◽  
Pharmacokinetic Profile ◽  
Advanced Solid Tumors ◽  
Daily Dose

REO-001: A phase I trial of percutaneous intralesional administration of reovirus type 3 dearing (Reolysin®) in patients with advanced solid tumors

2012 ◽  
Vol 31 (3) ◽  
pp. 696-706 ◽  
Author(s):  
Don G. Morris ◽  
Xiaolan Feng ◽  
Lisa M. DiFrancesco ◽  
Kevin Fonseca ◽  
Peter A Forsyth ◽  
...  
Keyword(s):  
Phase I ◽  
Solid Tumors ◽  
Phase I Trial ◽  
Advanced Solid Tumors ◽  
Reovirus Type ◽  
Intralesional Administration ◽  
Type 3

Abstract CT115: Phase I trial of the triplet berzosertib (M6620, VX-970), veliparib and cisplatin (BVP) in patients with advanced solid tumors

2021 ◽  
Author(s):  
Geraldine O'Sullivan Coyne ◽  
Khanh T. Do ◽  
Shivaani Kummar ◽  
Naoko Takebe ◽  
Sarina Piha-Paul ◽  
...  
Keyword(s):  
Phase I ◽  
Solid Tumors ◽  
Phase I Trial ◽  
Advanced Solid Tumors

Phase I trial of 9-aminocamptothecin in children with refractory solid tumors: a Pediatric Oncology Group study.

1998 ◽  
Vol 16 (7) ◽  
pp. 2494-2499 ◽  
Author(s):  
A M Langevin ◽  
D T Casto ◽  
P J Thomas ◽  
S D Weitman ◽  
C Kretschmar ◽  
...  
Keyword(s):  
Steady State ◽  
Phase I ◽  
Solid Tumors ◽  
Phase I Trial ◽  
Malignant Tumors ◽  
Hepatic Metabolism ◽  
Pharmacokinetic Profile ◽  
Maximum Tolerated Dose ◽  
Volume Of Distribution ◽  
Recommended Phase Ii Dose

PURPOSE A phase I trial of 9-aminocamptothecin (9-AC) was performed in children with solid tumors to establish the dose-limiting toxicity (DLT), maximum-tolerated dose (MTD), and the pharmacokinetic profile in children and to document any evidence of activity. PATIENTS AND METHODS A 72-hour infusion of 9-AC dimethylacetamide formulation was administered every 21 days to 23 patients younger than 21 years of age with malignant tumors refractory to conventional therapy. Doses ranged from 36 to 62 microg/m2 per hour. Pharmacokinetics were to be performed in at least three patients per dose level. The first course was used to determine the DLT and MTD. RESULTS Nineteen patients on four dose levels were assessable for toxicities. At 62 microg/m2 per hour, three patients experienced dose-limiting neutropenia and one patient experienced dose-limiting thrombocytopenia. Pharmacokinetics were performed on 15 patients (nine patients had complete sets of plasma sampling performed). The pharmacokinetics of both lactone and total 9-AC were highly variable. The percentage of 9-AC lactone at steady-state was 10.8% +/- 3.6%. Total 9-AC and its lactone form had a terminal half-life of 8.1 +/- 3.8 and 7.1 +/- 3.9 hours, respectively, and a volume of distribution at steady-state (Vdss) of 21.2 +/- 13.3 L/m2 and 135.3 +/- 52.5 L/m2, respectively. Hepatic metabolism and biliary transport had an important role in 9-AC disposition. CONCLUSION The recommended phase II dose of 9-AC administered as a 72-hour infusion every 21 days to children with solid tumors is 52 microg/m2 per hour. Neutropenia and thrombocytopenia were dose limiting.

Abstract 4500: Combined mTOR inhibition and autophagy inhibition: Phase I trial of temsirolimus and hydroxchloroquine in patients with advanced solid tumors

2011 ◽  
Author(s):  
Kenneth M. Algazy ◽  
Lynn M. Schuchter ◽  
Angela M. Demichele ◽  
Vaughn J. David ◽  
Drew A. Torigian ◽  
...  
Keyword(s):  
Phase I ◽  
Solid Tumors ◽  
Phase I Trial ◽  
Advanced Solid Tumors ◽  
Mtor Inhibition ◽  
Autophagy Inhibition

Abstract CT066: First-in-human phase I trial of the oral PLK4 inhibitor CFI-400945 in patients with advanced solid tumors

2016 ◽  
Author(s):  
Philippe L. Bedard ◽  
David W. Cescon ◽  
Graham Fletcher ◽  
Trish Denny ◽  
Richard Brokx ◽  
...  
Keyword(s):  
Phase I ◽  
Solid Tumors ◽  
Phase I Trial ◽  
Advanced Solid Tumors

Abstract 3014: Pharmacokinetics of the CDC7 inhibitor LY3143921 hydrate, a CRUK first-in-human phase I trial in patients with advanced solid tumors

2020 ◽  
Author(s):  
Shelby Barnett ◽  
Melanie Griffin ◽  
Richard H. Wilson ◽  
Elizabeth R. Plummer ◽  
Jeffry T. Evans ◽  
...  
Keyword(s):  
Phase I ◽  
Solid Tumors ◽  
Phase I Trial ◽  
Advanced Solid Tumors
Sign in / Sign up

Export Citation Format

Share Document